Hyperimmuneglobulin for cytomegalovirus prophylaxis following heart transplantation.
Cytomegalovirus continues to be an important cause of morbidity and mortality following organ transplantation. In a series of 75 heart transplant patients, we have compared two protocols for prophylactic administration of CMV hyperimmuneglobulin. The first group of patients received immunoglobulin on the operative and on the tenth postoperative days. The second group of patients received immunoglobulins on the operative day, and repeatedly with each period of increased immunosuppression. With repeated doses of immunoglobulin prophylaxis, the incidence of CMV reactivation and the clinical severity of CMV infection were both significantly reduced. A reduction in the incidence of CMV infection in recipients who were seronegative preoperatively was also observed. (5/8 vs. 7/25 patients; P = 0.06). We conclude that repeated administration of specific hyperimmuneglobulin with each period of increased immunosuppression following heart transplantation has a beneficial effect on both CMV reactivation and infection.
D000328:Adult; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D004334:Drug Administration Schedule; D005260:Female; D016027:Heart Transplantation; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D011183:Postoperative Complications / Q000517:prevention & control*; D012008:Recurrence
D007136:Immunoglobulins; D007166:Immunosuppressive Agents